LAUSR

&NA; Micronized cocrystal powders and amorphous spray‐dried formulations were prepared and evaluated in vivo and in vitro as pulmonary absorption enhancement formulations of poorly soluble itraconazole (ITZ). ITZ cocrystals with succinic acid (SA) or l‐tartaric acid (TA) with a particle size diameter of <2 &mgr;m were successfully micronized using the jet‐milling system. The cocrystal crystalline morphologies observed using scanning electron microscopy (SEM) suggested particle shapes that differed from those of the crystalline or spray‐dried amorphous ITZ. The micronized ITZ cocrystal powders showed better intrinsic dissolution rate (IDR) and pulmonary absorption profile in rats than that of the amorphous spray‐dried formulation and crystalline ITZ with comparable particle sizes. Specifically, in rat pharmacokinetic studies following pulmonary administration, micronized ITZ‐SA and ITZ‐TA cocrystals showed area under the curve from 0 to 8 h (AUC0–8h) values approximately 24‐ and 19‐fold higher than those of the crystalline ITZ and 2.0‐ and 1.6‐fold higher than the spray‐dried ITZ amorphous values, respectively. The amorphous formulation appeared physically instable during the studies due to rapid crystallization of ITZ, which was its disadvantage compared to the crystalline formulations. Therefore, this study demonstrated that micronized cocrystals are promising formulations for enhancing the pulmonary absorption of poorly soluble compounds. Graphical abstract Figure. No caption available.